{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:37:31Z","timestamp":1791632251764,"version":"4.3.4"},"reference-count":116,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Modern diabetes therapy extends beyond glycemic control and increasingly focuses on comprehensive risk reduction to prevent long-term complications, improve quality of life, and reduce premature mortality. Accordingly, modern therapeutic approaches address not only glucose metabolism but also cardiovascular, renal, and metabolic consequences of diabetes. Within this context, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a significant therapeutic class. In addition to their well-known effects on glycemic control and the metabolic-cardiovascular-renal axis, increasing evidence suggests that these agents may exert a range of pleiotropic effects and opening new therapeutic venues, discussed in this review. Methods: A narrative review of the literature was conducted using the PubMed, Scopus, and Google Scholar databases. Publications from 2014 and 2026 were screened using predefined keywords related to GLP-1 RAs and their potential effects across multiple physiological systems and diseases. Notably, more than 80% of the included studies were published between 2020 and 2026, reflecting the recent growth of research in this field. Results: GLP-1 RAs have been associated with beneficial effects across a wide range of conditions, including substance use disorders, mental health disorders, neurodegenerative diseases, obesity-related complications, liver disease, genitourinary disorders, osteoarthritis, and sleep apnea. While they are currently the most effective pharmacological agents for the treatment of obesity, they also significantly reduce hepatic steatosis and are associated with a decreased risk of developing hepatocellular carcinoma. Furthermore, they have also demonstrated positive effects against prostate cancer, polycystic ovary syndrome (PCOS), improved libido and fertility. Conclusions: GLP-1 RAs should no longer be regarded solely as antihyperglycemic agents. Instead, they represent a versatile therapeutic class with expanding clinical relevance across multiple medical disciplines. While current evidence is promising, further large-scale, well-designed clinical trials are required to define their full therapeutic potential.<\/jats:p>","DOI":"10.3390\/jcm15072786","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:40:31Z","timestamp":1775554831000},"page":"2786","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Beyond Glycemic Control: GLP-1RA\u2013Based Therapies and Emerging Targets Beyond the Metabolic Axis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8279-0373","authenticated-orcid":false,"given":"Wojciech","family":"Matuszewski","sequence":"first","affiliation":[{"name":"Clinic of Endocrinology, Diabetology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Wo\u0142os-K\u0142osowicz","sequence":"additional","affiliation":[{"name":"Clinic of Endocrinology, Diabetology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"W\u0142odarczyk","sequence":"additional","affiliation":[{"name":"Department of Human Physiology and Pathophysiology, University of Warmia and Mazury, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Wa\u015bniewska","sequence":"additional","affiliation":[{"name":"Department of Human Physiology and Pathophysiology, University of Warmia and Mazury, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Modzelewski","sequence":"additional","affiliation":[{"name":"Clinic of Endocrinology, Diabetology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8167-6658","authenticated-orcid":false,"given":"Jan Marek","family":"G\u00f3rny","sequence":"additional","affiliation":[{"name":"Clinic of Endocrinology, Diabetology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Szklarz","sequence":"additional","affiliation":[{"name":"Clinic of Endocrinology, Diabetology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4793-8711","authenticated-orcid":false,"given":"Miko\u0142aj","family":"Madeksza","sequence":"additional","affiliation":[{"name":"Clinic of Endocrinology, Diabetology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judyta","family":"Juranek","sequence":"additional","affiliation":[{"name":"Department of Human Physiology and Pathophysiology, University of Warmia and Mazury, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1517\/17460441.2013.741580","article-title":"Discovery and development of exenatide: The first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1","volume":"8","author":"Parkes","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/14656566.2017.1282463","article-title":"Exenatide: Pharmacokinetics, clinical use, and future directions","volume":"18","author":"Knop","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2478488","DOI":"10.1080\/0886022X.2025.2478488","article-title":"Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: Evidence from Mendelian randomization","volume":"47","author":"Yao","year":"2025","journal-title":"Ren. Fail."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pcad.2024.12.010","article-title":"Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy","volume":"89","author":"Franco","year":"2025","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: A prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: A secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Li, Q.X., Gao, H., Guo, Y.X., Wang, B.Y., Hua, R., Gao, L., Shang, H.W., Lu, X., and Xu, J.D. (2021). GLP-1 and Underlying Beneficial Actions in Alzheimer\u2019s Disease, Hypertension, and NASH. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.721198"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Nauck, M.A., and Quast, D.R. (2021). Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.645566"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-Weekly Semaglutide in Adolescents with Obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.125.074545","article-title":"Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial","volume":"151","author":"Marx","year":"2025","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2337\/dc23-0231","article-title":"Dulaglutide and Kidney Function\u2013Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis","volume":"46","author":"Botros","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ejhf.3478","article-title":"Cardiovascular Outcomes with Exenatide in Type 2 Diabetes According to Ejection Fraction: The EXSCEL Trial","volume":"27","author":"Neves","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"111617","DOI":"10.1016\/j.diabres.2024.111617","article-title":"The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials","volume":"210","author":"Sheng","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1111\/dom.70481","article-title":"Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial","volume":"28","author":"Fountoulakis","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/dom.14954","article-title":"Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial","volume":"25","author":"Gerstein","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/ehjcvp\/pvae006","article-title":"Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial","volume":"10","author":"Krychtiuk","year":"2024","journal-title":"Eur. Heart J.\u2014Cardiovasc. Pharmacother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial","volume":"330","author":"Rosenstock","year":"2023","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e12734","DOI":"10.1111\/cob.12734","article-title":"Time to weight plateau with tirzepatide treatment in the SURMOUNT -1 and SURMOUNT -4 clinical trials","volume":"15","author":"Horn","year":"2025","journal-title":"Clin. Obes."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","first-page":"agaf069","article-title":"GLP-1 receptor agonists and alcohol use disorder: A systematic review","volume":"61","author":"Patel","year":"2025","journal-title":"Alcohol. Alcohol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Schooling, C.M., Yang, G., Soliman, G.A., and Leung, G.M. (2025). A Hypothesis That Glucagon-like Peptide-1 Receptor Agonists Exert Immediate and Multifaceted Effects by Activating Adenosine Monophosphate-Activate Protein Kinase (AMPK). Life, 15.","DOI":"10.3390\/life15020253"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.neuropharm.2018.01.013","article-title":"GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence","volume":"136","author":"Jerlhag","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"bqaf028","DOI":"10.1210\/endocr\/bqaf028","article-title":"GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder","volume":"166","author":"Jerlhag","year":"2025","journal-title":"Endocrinology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13098-025-02006-x","article-title":"Repurposing GLP-1 receptor agonists for alcohol use disorder: A systematic review and meta-analysis","volume":"18","author":"Nasrollahizadeh","year":"2026","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"bvaf141","DOI":"10.1210\/jendso\/bvaf141","article-title":"GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer","volume":"9","author":"Srinivasan","year":"2025","journal-title":"J. Endocr. Soc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12991-024-00527-9","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: A systematic review","volume":"23","author":"Lee","year":"2024","journal-title":"Ann. Gen. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nn.4540","article-title":"GLP-1 acts on habenular avoidance circuits to control nicotine intake","volume":"20","author":"Tuesta","year":"2017","journal-title":"Nat. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.7326\/M23-2718","article-title":"Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes: Target Trial Emulation Using Real-World Data","volume":"177","author":"Wang","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"112424","DOI":"10.1016\/j.drugalcdep.2024.112424","article-title":"Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials","volume":"264","author":"Martinelli","year":"2024","journal-title":"Drug Alcohol. Depend."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41386-018-0010-3","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats","volume":"43","author":"Hernandez","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Mugari, I. (2024). The Emerging Trends and Response to Drug and Substance Abuse among the Youth in Zimbabwe. Soc. Sci., 13.","DOI":"10.3390\/socsci13090469"},{"key":"ref_42","unstructured":"Al Khouri, I., Iannaccone, B., and Fulajtarova, M. (2024). Trends in Substance Use Among Young People in the EU: A Secondary Analysis of Available Data. Addictology, 24."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.36128\/PRIW.VI55.1074","article-title":"Aktualne tendencje przest\u0119pczo\u015b\u0107 narkotykowej oraz za\u017cywania narkotyk\u00f3w w\u015br\u00f3d nieletnich w Polsce","volume":"55","author":"Stachelska","year":"2025","journal-title":"Prawo Wi\u0119\u017a"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41386-021-01153-9","article-title":"The neurobiology of drug addiction: Cross-species insights into the dysfunction and recovery of the prefrontal cortex","volume":"47","author":"Ceceli","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Beheshti, I. (2023). Cocaine Destroys Gray Matter Brain Cells and Accelerates Brain Aging. Biology, 12.","DOI":"10.3390\/biology12050752"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Egecioglu, E., Engel, J.A., and Jerlhag, E. (2013). The Glucagon-Like Peptide 1 Analogue, Exendin-4, Attenuates the Rewarding Properties of Psychostimulant Drugs in Mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0069010"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"109872","DOI":"10.1016\/j.pnpbp.2020.109872","article-title":"The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: Relevance for bipolar disorder","volume":"99","author":"Cunha","year":"2020","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","article-title":"Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: A retrospective cohort study","volume":"29","author":"Wang","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Arillotta, D., Floresta, G., Papanti Pelletier, G.D., Guirguis, A., Corkery, J.M., Martinotti, G., and Schifano, F. (2024). Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach. Brain Sci., 14.","DOI":"10.3390\/brainsci14060617"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1017\/neu.2025.10038","article-title":"Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: A systematic review","volume":"37","author":"Au","year":"2025","journal-title":"Acta Neuropsychiatr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e2435247","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev-clinpsy-072220-021440","article-title":"Major Depression and Its Recurrences: Life Course Matters","volume":"18","author":"Monroe","year":"2022","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11920-018-0893-z","article-title":"Psychological Pain, Depression, and Suicide: Recent Evidences and Future Directions","volume":"20","author":"Conejero","year":"2018","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/14740338.2024.2335215","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: What do we know and future vistas","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Zhou, J., Zheng, Y., Xu, B., Long, S., Zhu Le Liu, Y., Li, C., Zhang, Y., Liu, M., and Wu, X. (2024). Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: A pharmacovigilance study based on the FDA Adverse Event Reporting System database. BMC Med., 22.","DOI":"10.1186\/s12916-024-03274-6"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"121546","DOI":"10.1016\/j.lfs.2023.121546","article-title":"Dulaglutide impedes depressive-like behavior persuaded by chronic social defeat stress model in male C57BL\/6 mice: Implications on GLP-1R and cAMP\/PKA signaling pathway in the hippocampus","volume":"320","author":"Darwish","year":"2023","journal-title":"Life Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis","volume":"32","author":"Chen","year":"2024","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00115-025-01813-x","article-title":"Glucagon-like-peptide-1-Rezeptoragonisten: Eine neue pharmakologische Behandlungsoption f\u00fcr psychiatrische Erkrankungen?","volume":"96","author":"Himmerich","year":"2025","journal-title":"Nervenarzt"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"112","DOI":"10.12659\/MSMBR.891168","article-title":"Exenatide Treatment Exerts Anxiolytic- and Antidepressant-Like Effects and Reverses Neuropathy in a Mouse Model of Type-2 Diabetes","volume":"20","author":"Mutlu","year":"2014","journal-title":"Med. Sci. Monit. Basic Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.euroneuro.2025.08.002","article-title":"Repurposing glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of depression: A systematic review of preclinical, observational and clinical investigations","volume":"99","author":"Li","year":"2025","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/eurheartj\/ehae613","article-title":"Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: The FLOW trial","volume":"46","author":"Mahaffey","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Li, W., Liang, X., Sun, N., and Zhang, D. (2025). Influence of glucagon-like peptide-1 receptor agonists on renal parameters: A meta-analysis of randomized controlled trials. BMC Endocr. Disord., 25.","DOI":"10.1186\/s12902-025-01948-7"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","article-title":"Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products\u2013induced inflammation","volume":"105","author":"Sourris","year":"2024","journal-title":"Kidney Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"155985","DOI":"10.1016\/j.prp.2025.155985","article-title":"The critical role of GLP-1 signaling pathways in the pathology of Parkinson\u2019s disease and diabetes","volume":"270","author":"Chen","year":"2025","journal-title":"Pathol.\u2014Res. Pr."},{"key":"ref_66","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12672-025-01878-9","article-title":"Targeting obesity, metabolic syndrome, and prostate cancer: GLP-1 agonists as emerging therapeutic agents","volume":"16","author":"Murphy","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cmet.2021.03.019","article-title":"Insulin action in adipocytes, adipose remodeling, and systemic effects","volume":"33","author":"Santoro","year":"2021","journal-title":"Cell Metab."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Cancel, M., Pouillot, W., Mah\u00e9o, K., Fontaine, A., Crott\u00e8s, D., and Fromont, G. (2022). Interplay between Prostate Cancer and Adipose Microenvironment: A Complex and Flexible Scenario. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810762"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1590\/s1677-5538.ibju.2018.0261","article-title":"Role of Adiponectin in prostate cancer","volume":"45","author":"Hu","year":"2019","journal-title":"Int. Braz. J. Urol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_72","unstructured":"Birbrair, A. (2020). Adipocytes in the Tumour Microenvironment. Tumor Microenvironment, Springer International Publishing. Available online: http:\/\/link.springer.com\/10.1007\/978-3-030-37184-5_1."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.2217\/fon-2016-0061","article-title":"Metabolic Syndrome in Prostate Cancer: Impact on Risk and Outcomes","volume":"12","author":"Karzai","year":"2016","journal-title":"Future Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc17-1825","article-title":"Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial","volume":"41","author":"Nauck","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Levy, S., Attia, A., Elshazli, R.M., Abdelmaksoud, A., Tatum, D., Aiash, H., and Toraih, E.A. (2024). Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million Patients. Cancers, 17.","DOI":"10.3390\/cancers17010078"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1158\/1538-7445.AM2023-735","article-title":"Abstract 735: The associations between the use of GLP-1 receptor agonists, cancer recurrence and all-cause mortality among cancer survivors","volume":"83","author":"Chen","year":"2023","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"173102","DOI":"10.1016\/j.ejphar.2020.173102","article-title":"Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line","volume":"878","author":"Eftekhari","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Du, H., Meng, X., Yao, Y., and Xu, J. (2022). The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer\u2019s disease. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1033479"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41591-025-03542-9","article-title":"Author Correction: Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat. Med."},{"key":"ref_81","first-page":"16","article-title":"Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer\u2019s Disease","volume":"19","author":"Colin","year":"2023","journal-title":"Eur. Endocrinol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"113537","DOI":"10.1016\/j.intimp.2024.113537","article-title":"Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study","volume":"143","author":"Siddeeque","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1021\/acschemneuro.4c00729","article-title":"Dual GLP-1 and GIP Agonist Tirzepatide Exerted Neuroprotective Action in a Parkinson\u2019s Disease Rat Model","volume":"16","author":"Delvadia","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"ref_84","first-page":"001","article-title":"Efficacy and safety of glucagon-like peptide 1 agonists for Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"83","author":"Nogueira","year":"2025","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s13098-025-01888-1","article-title":"GLP-1 receptor agonists in Parkinson\u2019s disease: An updated comprehensive systematic review with meta-analysis","volume":"17","author":"Helal","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e70075","DOI":"10.1111\/ene.70075","article-title":"GLP -1 Agonists as Potential Neuromodulators in Development of Parkinson\u2019s Disease: A Nationwide Cohort Study","volume":"32","author":"Gamborg","year":"2025","journal-title":"Eur. J. Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/mds.29992","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson\u2019s Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study","volume":"39","author":"Tang","year":"2024","journal-title":"Mov. Disord."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11892-025-01606-1","article-title":"Targeting Metabolic Dysfunction in Parkinson\u2019s Disease: The Role of GLP-1 Agonists in Body Weight Regulation and Neuroprotection","volume":"25","author":"Portugal","year":"2025","journal-title":"Curr. Diab Rep."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Mo\u021b\u0103\u021b\u0103ianu, A., M\u0103nescu, I.B., \u0218erban, G., B\u0103rcu\u021bean, L., Ion, V., B\u0103la\u0219a, R., and Andone, S. (2024). Exploring the Role of Metabolic Hormones in Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25105059"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1111\/dom.15898","article-title":"Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study","volume":"26","author":"Arai","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1111\/dom.15524","article-title":"The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis","volume":"26","author":"Abdelmalek","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/13543784.2025.2473062","article-title":"The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: A review for gastroenterologists","volume":"34","author":"Alkhouri","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Bernsmeier, C., Meyer-Gerspach, A.C., Blaser, L.S., Jeker, L., Steinert, R.E., Heim, M.H., and Beglinger, C. (2014). Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087488"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","article-title":"Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes","volume":"167","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1186\/s12967-024-05753-z","article-title":"GLP-1R activation attenuates the progression of pulmonary fibrosis via disrupting NLRP3 inflammasome\/PFKFB3-driven glycolysis interaction and histone lactylation","volume":"22","author":"Liu","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s13679-024-00592-x","article-title":"Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials","volume":"13","author":"Beccuti","year":"2024","journal-title":"Curr. Obes. Rep."},{"key":"ref_99","first-page":"121","article-title":"Targeting the GLP-1\/GLP-1R axis to treat osteoarthritis: A new opportunity?","volume":"32","author":"Meurot","year":"2022","journal-title":"J. Orthop. Transl."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/14656566.2024.2391524","article-title":"The impact of approved anti-obesity medications on osteoarthritis","volume":"25","author":"Baser","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s42399-025-02000-4","article-title":"Efficacy and Safety of GLP-1 Receptor Agonists for the Management of Knee Osteoarthritis: A Systematic Review and Meta-Analysis","volume":"7","author":"Singh","year":"2025","journal-title":"SN Compr. Clin. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-18-0175","article-title":"Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: A pilot randomized study","volume":"179","author":"Salamun","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., and Madej, P. (2022). The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084334"},{"key":"ref_104","first-page":"17455057241234530","article-title":"A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS","volume":"20","author":"Bader","year":"2024","journal-title":"Women\u2019s Health"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"108834","DOI":"10.1016\/j.jdiacomp.2024.108834","article-title":"The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials","volume":"38","author":"Rodrigues","year":"2024","journal-title":"J. Diabetes Complicat."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e240529","DOI":"10.1530\/EC-24-0529","article-title":"Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review","volume":"14","author":"Monney","year":"2025","journal-title":"Endocr. Connect."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/17512433.2021.1933433","article-title":"Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome","volume":"14","author":"Siamashvili","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2042018821989238","DOI":"10.1177\/2042018821989238","article-title":"The potential role of incretin-based therapies for polycystic ovary syndrome: A narrative review of the current evidence","volume":"12","author":"Abdalla","year":"2021","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1210\/jc.2008-0115","article-title":"Comparison of Single and Combined Treatment with Exenatide and Metformin on Menstrual Cyclicity in Overweight Women with Polycystic Ovary Syndrome","volume":"93","author":"Marrioneaux","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_110","first-page":"e66691","article-title":"Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women with Polycystic Ovary Syndrome: A Scoping Review","volume":"16","author":"Shunk","year":"2024","journal-title":"Cureus"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/andr.70022","article-title":"Effects of glucagon-like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta-analysis","volume":"13","author":"Salvio","year":"2025","journal-title":"Andrology"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"La Vignera, S., Condorelli, R.A., Calogero, A.E., Cannarella, R., and Aversa, A. (2023). Sexual and Reproductive Outcomes in Obese Fertile Men with Functional Hypogonadism after Treatment with Liraglutide: Preliminary Results. J. Clin. Med., 12.","DOI":"10.3390\/jcm12020672"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Yuan, P., Ma, D., Gao, X., Wang, J., Li, R., Liu, Z., Wang, T., Wang, S., Liu, J., and Liu, X. (2020). Liraglutide Ameliorates Erectile Dysfunction via Regulating Oxidative Stress, the RhoA\/ROCK Pathway and Autophagy in Diabetes Mellitus. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.01257"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejps.2015.01.010","article-title":"Pro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia","volume":"70","author":"Zhang","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Tamilwanan, S., Aziz, Z., Rong, L.Y., Bitar, A.N., Zarzour, R.H.A., and Alshehade, S.A. (2025). Efficacy of GLP-1 receptor agonists and dual GLP-1\/GIP receptor agonists in managing MALFD: A meta-analysis of randomized controlled trials. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-04358-0"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1053\/j.gastro.2025.06.003","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis","volume":"169","author":"Chiang","year":"2025","journal-title":"Gastroenterology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2786\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T10:08:37Z","timestamp":1775556517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":116,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15072786"],"URL":"https:\/\/doi.org\/10.3390\/jcm15072786","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]}}}